Effects of dalcetrapib in patients with a recent acute coronary syndrome

Gregory G Schwartz; Anders G Olsson; Markus Abt; Christie M Ballantyne; Philip J Barter; Jochen Brumm; Bernard R Chaitman; Ingar M Holme; David Kallend; Lawrence A Leiter; Eran Leitersdorf; John J V McMurray; Hardi Mundl; Stephen J Nicholls; Prediman K Shah; Jean-Claude Tardif; R Scott Wright; dal-OUTCOMES Investigators

doi:10.1056/NEJMoa1206797

Effects of dalcetrapib in patients with a recent acute coronary syndrome

Gregory G Schwartz, Anders G Olsson, Markus Abt, Christie M Ballantyne, Philip J Barter, Jochen Brumm, Bernard R Chaitman, Ingar M Holme, David Kallend, Lawrence A Leiter, Eran Leitersdorf, John J V McMurray, Hardi Mundl, Stephen J Nicholls, Prediman K Shah, Jean-Claude Tardif, R Scott Wright, dal-OUTCOMES Investigators

Hjertemedicinsk Afdeling AHH

1817 Citationer (Scopus)

Abstract

In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events. However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain. Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes.

Originalsprog	Engelsk
Tidsskrift	The New England journal of medicine
Vol/bind	367
Udgave nummer	22
Sider (fra-til)	2089-99
Antal sider	11
ISSN	0028-4793
DOI	https://doi.org/10.1056/NEJMoa1206797
Status	Udgivet - 29 nov. 2012

Adgang til dokumentet

10.1056/NEJMoa1206797

Andre filer og links

Link to publication in Scopus

Citationsformater

Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., Leitersdorf, E., McMurray, J. J. V., Mundl, H., Nicholls, S. J., Shah, P. K., Tardif, J.-C., Wright, R. S., & dal-OUTCOMES Investigators (2012). Effects of dalcetrapib in patients with a recent acute coronary syndrome. The New England journal of medicine, 367(22), 2089-99. https://doi.org/10.1056/NEJMoa1206797

Schwartz, GG, Olsson, AG, Abt, M, Ballantyne, CM, Barter, PJ, Brumm, J, Chaitman, BR, Holme, IM, Kallend, D, Leiter, LA, Leitersdorf, E, McMurray, JJV, Mundl, H, Nicholls, SJ, Shah, PK, Tardif, J-C, Wright, RS & dal-OUTCOMES Investigators 2012, 'Effects of dalcetrapib in patients with a recent acute coronary syndrome', The New England journal of medicine, bind 367, nr. 22, s. 2089-99. https://doi.org/10.1056/NEJMoa1206797

@article{8f5a2beb6a2a43128b9a50a24c95c86d,

title = "Effects of dalcetrapib in patients with a recent acute coronary syndrome",

abstract = "In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events. However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain. Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes.",

keywords = "Acute Coronary Syndrome, Aged, Anticholesteremic Agents, Apolipoproteins, Biological Markers, Blood Pressure, C-Reactive Protein, Cardiovascular Diseases, Cholesterol Ester Transfer Proteins, Cholesterol, HDL, Cholesterol, LDL, Female, Humans, Male, Middle Aged, Recurrence, Risk, Sulfhydryl Compounds, Triglycerides",

author = "Schwartz, \{Gregory G\} and Olsson, \{Anders G\} and Markus Abt and Ballantyne, \{Christie M\} and Barter, \{Philip J\} and Jochen Brumm and Chaitman, \{Bernard R\} and Holme, \{Ingar M\} and David Kallend and Leiter, \{Lawrence A\} and Eran Leitersdorf and McMurray, \{John J V\} and Hardi Mundl and Nicholls, \{Stephen J\} and Shah, \{Prediman K\} and Jean-Claude Tardif and Wright, \{R Scott\} and \{dal-OUTCOMES Investigators\}",

year = "2012",

month = nov,

day = "29",

doi = "10.1056/NEJMoa1206797",

language = "English",

volume = "367",

pages = "2089--99",

journal = "The New England journal of medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "22",

}

TY - JOUR

T1 - Effects of dalcetrapib in patients with a recent acute coronary syndrome

AU - Schwartz, Gregory G

AU - Olsson, Anders G

AU - Abt, Markus

AU - Ballantyne, Christie M

AU - Barter, Philip J

AU - Brumm, Jochen

AU - Chaitman, Bernard R

AU - Holme, Ingar M

AU - Kallend, David

AU - Leiter, Lawrence A

AU - Leitersdorf, Eran

AU - McMurray, John J V

AU - Mundl, Hardi

AU - Nicholls, Stephen J

AU - Shah, Prediman K

AU - Tardif, Jean-Claude

AU - Wright, R Scott

AU - dal-OUTCOMES Investigators

PY - 2012/11/29

Y1 - 2012/11/29

N2 - In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events. However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain. Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes.

AB - In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events. However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain. Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes.

KW - Acute Coronary Syndrome

KW - Aged

KW - Anticholesteremic Agents

KW - Apolipoproteins

KW - Biological Markers

KW - Blood Pressure

KW - C-Reactive Protein

KW - Cardiovascular Diseases

KW - Cholesterol Ester Transfer Proteins

KW - Cholesterol, HDL

KW - Cholesterol, LDL

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Recurrence

KW - Risk

KW - Sulfhydryl Compounds

KW - Triglycerides

UR - https://www.scopus.com/pages/publications/84870045994

U2 - 10.1056/NEJMoa1206797

DO - 10.1056/NEJMoa1206797

M3 - Journal article

C2 - 23126252

SN - 0028-4793

VL - 367

SP - 2089

EP - 2099

JO - The New England journal of medicine

JF - The New England journal of medicine

IS - 22

ER -

Effects of dalcetrapib in patients with a recent acute coronary syndrome

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater